Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

BriaCell Therapeutics Corp. (BCTX)

7.45   0.28 (3.91%) 03-31 16:00
Open: 7.3 Pre. Close: 7.17
High: 7.49 Low: 7.1468
Volume: 158,997 Market Cap: 116(M)

Technical analysis

as of: 2023-03-31 4:17:03 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 8.87     One year: 10.36
Support: Support1: 6.64    Support2: 6.05
Resistance: Resistance1: 7.59    Resistance2: 8.87
Pivot: 7
Moving Average: MA(5): 7.16     MA(20): 6.94
MA(100): 6.37     MA(250): 6.38
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 87.7     %D(3): 80.9
RSI: RSI(14): 58.5
52-week: High: 12.09  Low: 4.05
Average Vol(K): 3-Month: 206 (K)  10-Days: 82 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ BCTX ] has closed Bollinger Bands are 49.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.45 - 7.48 7.48 - 7.5
Low: 6.73 - 6.76 6.76 - 6.79
Close: 7.12 - 7.17 7.17 - 7.21

Company Description

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Headline News

Fri, 31 Mar 2023
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy - Investing News Network

Thu, 30 Mar 2023
BriaCell plans spin-out of pre-clinical assets into new entity (BCTX) - Seeking Alpha

Thu, 30 Mar 2023
BriaCell Therapeutics (BCTX) to Spin-Out Certain Pre-Clinical ... -

Fri, 24 Mar 2023
Evolution of Oncology Treatments Giving New Hope to Those ... - PR Newswire

Tue, 21 Mar 2023
FDA’s Wave of Fast Track Designations Pushing Momentum in Healthcare Sector in 2023 -

Wed, 15 Mar 2023
BriaCell to Present Clinical and Survival Data in Advanced ... - GlobeNewswire

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 16 (M)
Shares Float 11 (M)
% Held by Insiders 23.7 (%)
% Held by Institutions 17.2 (%)
Shares Short 1,600 (K)
Shares Short P.Month 1,510 (K)

Stock Financials

EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.08
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -28.7
Return on Equity (ttm) -111.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.23
Qtrly Earnings Growth 0
Operating Cash Flow -16 (M)
Levered Free Cash Flow -12 (M)

Stock Valuations

PE Ratio 745
PEG Ratio 0
Price to Book value -93.13
Price to Sales 0
Price to Cash Flow -7.4

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2020-01-01
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.